Adaptation of a Mobile Interactive Obesity Treatment Approach for Early Severe Mental Illness: Protocol for a Mixed Methods Implementation and Pilot Randomized Controlled Trial
Source : https://www.researchprotocols.org/2023/1/e42114
Background: Obesity is common in individuals with severe mental illness (SMI), contributing to a significantly shortened lifespan when compared to the general population. Available weight loss treatments have attenuated efficacy...
Conclusions: In this type 1 hybrid study design, we apply an evidence-based treatment adaptation framework to plan, adapt, and feasibility test a mobile health intervention in real-world treatment settings. Resting at the intersection of community mental health treatment and physical health promotion, this study aims to advance the use of...
Share
Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37293487/
Exposure to a CAF diet during the early stages of obesity reduces the effects of peripheral and central GLP1R agonists, and WAT does not express a functional GLP1 receptor. These...
Discussion: Exposure to a CAF diet during the early stages of obesity reduces the effects of peripheral and central GLP1R agonists, and WAT does not express a functional GLP1 receptor. These data support that exposure to the obesogenic food environment, without the development or manifestation of obesity, can alter the response to GLP1R...
Share
Perspectives on weight control in diabetes - Tirzepatide - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37279858/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: These findings suggest that the robust weight loss and associated changes are important contributors to the clinical profile of tirzepatide for the treatment of T2D diabetes and serve as the basis for further investigations including clinical outcomes.
Share
Conclusions: The combination of aerobic training and semaglutide treatment synergistically improved β-cell secretory function.
Share
Relevance: Novo Nordisk, the drug’s developer, announced the study’s topline results in a press release. On average, participants experienced a 15.1% decrease in weight after receiving the medication, regardless of treatment adherence, compared with a 2.4% weight loss with the placebo. The amount of weight loss with oral semaglutide was...
Share